Contemporary Pediatrics

Contemporary Pediatrics Expert Clinical Advice for Today's Pediatrician

Moving from pediatric to adult diabetes care is more than transferring a medical record. How can pediatric diabetes team...
09/24/2026

Moving from pediatric to adult diabetes care is more than transferring a medical record. How can pediatric diabetes teams better prepare young people for the move to adult care?

A new joint consensus report from ISPAD, EASD, and the ADA offers 31 statements covering the entire transition process, from early preparation through the first year after transfer.

Among the recommendations: Begin transition conversations 12 to 24 months before the anticipated transfer, assess transition readiness, maintain attention to psychosocial and mental health needs, provide a written medical summary to the adult team, and aim to schedule the first adult appointment within 3 to 4 months of the final pediatric visit.

The report also introduces the PROACT framework to help clinicians build a structured but adaptable approach to transition care.

Read more: https://hubs.li/Q04ygZgh0

Earlier mornings, homework, activities, and changing routines can all make sleep a challenge once children return to sch...
09/23/2026

Earlier mornings, homework, activities, and changing routines can all make sleep a challenge once children return to school.

Rashi Kochhar, MD, a pediatric pulmonologist and sleep medicine specialist, discusses what pediatricians should know about healthy sleep schedules, including age-based sleep needs, the importance of consistent bedtimes and wake times, and why teenagers may naturally struggle with early school mornings.

She also highlights an important clinical consideration: In younger children, insufficient or poor-quality sleep may present as hyperactivity or inattention rather than obvious daytime sleepiness.

Read more about how pediatricians can help families establish healthy sleep routines during the school year.

🔗https://hubs.li/Q04y9Q6_0

The FDA has granted Priority Review to a supplemental biologics license application for satralizumab (Enspryng) for the ...
09/21/2026

The FDA has granted Priority Review to a supplemental biologics license application for satralizumab (Enspryng) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in adults and adolescents aged 12 years or older.

The application is supported by results from the phase 3 METEOROID trial, in which satralizumab reduced the risk of MOGAD relapse by 68% compared with placebo. At 48 weeks, 87% of patients receiving satralizumab remained relapse-free compared with 67% receiving placebo.

MOGAD is a rare autoimmune inflammatory disorder that can affect the optic nerves, brain, and spinal cord, and there are currently no FDA-approved therapies for the condition. The FDA is expected to act on the application by January 10, 2027.

Read more: https://hubs.li/Q04x_qRJ0

For children with Lennox-Gastaut syndrome, how long should clinicians wait before assessing response to fenfluramine?A p...
09/21/2026

For children with Lennox-Gastaut syndrome, how long should clinicians wait before assessing response to fenfluramine?

A post hoc analysis found that patients transitioning from placebo to fenfluramine experienced reductions in seizures associated with a fall as early as 1 month after treatment initiation, with further improvement as doses increased. The study also documented improvements in global functioning reported by caregivers and investigators.

In a Q&A with Contemporary Pediatrics, Amélie Lothe, PhD, Global Medical Community Head for DEEs/Neurodevelopmental Disorders at UCB and an investigator on the study, discusses what these findings could mean for treatment expectations, dose optimization, adverse event monitoring, and assessing benefits beyond seizure counts.

🔗https://hubs.li/Q04x_40F0

🚨The FDA has approved levacetylleucine (Aqneursa) to treat ataxia in adults and pediatric patients with ataxia-telangiec...
09/18/2026

🚨The FDA has approved levacetylleucine (Aqneursa) to treat ataxia in adults and pediatric patients with ataxia-telangiectasia who weigh at least 15 kg. It is the first therapy approved for this rare neurodegenerative disorder.

The approval is based on a 73-patient randomized, double-blind, placebo-controlled crossover trial. Patients scored better on the functional Scale for Assessment and Rating of Ataxia (fSARA) on treatment than on placebo. The most common adverse reactions were fall, skin laceration, and urinary tract infection, and animal data suggest the drug may cause fetal harm.

The trial's 12-week periods leave open whether treatment alters long-term progression, and the indication covers ataxia only.

Full details for clinicians: https://hubs.li/Q04xV2mZ0

🚨The FDA has approved the first treatment for Sanfilippo syndrome type A (MPS IIIA): Fayuvi (rebisufligene etisparvovec-...
09/17/2026

🚨The FDA has approved the first treatment for Sanfilippo syndrome type A (MPS IIIA): Fayuvi (rebisufligene etisparvovec-hopf), a one-time intravenous AAV9 gene therapy that delivers a functional copy of the SGSH gene.

Until now, care for this rare, progressive neurodegenerative disease was limited to symptom management. In the pivotal trial, treated children maintained or improved cognitive function compared with an untreated historical control cohort — a divergence from the expected pattern of plateau and decline.

As with any single-arm, historically controlled approval, questions remain about durability of benefit and long-term safety, including a boxed warning for thrombotic microangiopathy.

We break down the trial data, mechanism, and what clinicians should watch for in the full article: https://hubs.li/Q04xPc6b0

09/17/2026

Creatine. Protein powders. Electrolytes. Caffeine. Pre-workout supplements.

As these products become more common among adolescent athletes, pediatricians may be hearing more questions from patients and families about what is safe, what works, and what should be avoided.

In this Notes on Nutrition article, Colleen Sloan, PA-C, RDN, provides a practical look at common sports supplements and how clinicians can approach these conversations. She also emphasizes an important point: No supplement can make up for inadequate nutrition.

From fueling with carbohydrates and meeting protein needs to understanding creatine, caffeine, hydration products, and supplement testing, here's what pediatricians should know when counseling young athletes.

Read the full article: https://hubs.li/Q04xNMz10

Could synbiotic supplementation help shape the gut microbiome early in life?In the randomized, double-blind, placebo-con...
09/16/2026

Could synbiotic supplementation help shape the gut microbiome early in life?

In the randomized, double-blind, placebo-controlled ARTEMIS trial, researchers evaluated a synbiotic containing 4 Bifidobacterium strains, 4 human milk oligosaccharides, and vitamin D in 114 infants and toddlers.

The supplement was well tolerated, with no significant differences in adverse events or gastrointestinal symptom burden compared with placebo. At least 1 administered strain was detected during supplementation in 72% of infants and 67% of toddlers who did not have the strain at baseline.

🔗https://hubs.li/Q04xG-z30

09/16/2026

What does diagnosing PMOS look like in adolescents?

For young patients, ultrasound may not always provide the answers clinicians need. In this reel, a pediatric and adolescent gynecologist explains some of the challenges with assessing ovarian morphology in this population.

Watch the reel and explore our full special report, “PCOS to PMOS: A long-awaited change.”

🔗https://hubs.li/Q04xGLYF0

The FDA has approved apitegromab-mstn (Isembyld) for spinal muscular atrophy (SMA) — the first therapy to directly targe...
09/14/2026

The FDA has approved apitegromab-mstn (Isembyld) for spinal muscular atrophy (SMA) — the first therapy to directly target muscle loss rather than motor neuron survival, for use alongside an existing SMN2-targeted treatment in patients 2 years and older.

In the phase 3 SAPPHIRE trial, patients receiving apitegromab 10 mg/kg gained 2.2 points on the Hammersmith Functional Motor Scale Expanded versus placebo at 1 year — while placebo patients, despite staying on SMN2 therapy, continued to decline.

Read more: https://hubs.li/Q04xntdJ0

Address

25115 Country Club Boulevard
North Olmsted, OH
44070

Website

Alerts

Be the first to know and let us send you an email when Contemporary Pediatrics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Contemporary Pediatrics:

Shortcuts

Share

Category